Last reviewed · How we verify
BC-3781
At a glance
| Generic name | BC-3781 |
|---|---|
| Also known as | Lefamulin |
| Sponsor | Nabriva Therapeutics AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis (PHASE1)
- Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) (PHASE2)
- Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia (PHASE3)
- Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia (PHASE3)
- A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781 (PHASE1)
- Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |